Richard Kenney

Company: Sonnet BioTherapeutics Inc.

Job title: CMO

Seminars:

A Tale of Two Forms of IL-12: The Benefits of Extending PK 2:40 pm

What challenges of dosing with rhIL-12 need to be overcome to finally see the benefits? How is SON-1010 (IL12-FHAB) specifically targeted to the TME? Gain an insight into the clinical development strategy for SON-1010Read more

day: Scientific Day Two